Irinotecan (CPT-11) is a cytotoxic drug that has wide applicability and usage in cancer 36 treatment. Despite its success, patients suffer dose-dependent diarrhea, limiting the 37 drug's efficacy. No effective therapy is available for this unmet medical need. Bacteria 38 β-glucuronidase (GUS) enzyme in the intestines plays a pivotal role in CPT-11 induced 39 diarrhea via reactivating the non-tox CPT-11 metabolite, SN-38G, back to toxic SN-38.
Introduction

73
Irinotecan (CPT-11) is a commonly used chemotherapeutic agent for the 74 treatment of malignances, such as cancers of brain, colon and lung, and refractory 75 forms of leukemia and lymphoma (1) . However, 88% of patients receiving CPT-11 suffer 76 from diarrhea, with 20-30% of them having severe diarrhea (CTCAE grades 3-4) (2).
77
This side effect increases patient suffering and, more importantly, prevents dose 
83
The underlying mechanism of CPT-11 induced diarrhea has been extensively 84 investigated. As a prodrug with a carbamate-linked dipiperidino moiety, CPT-11 is 85 hydrolyzed by carboxylesterases (CES) in vivo to remove the dipiperidino group and it is 86 then converted to its therapeutically active form SN-38. SN-38 inhibits type I DNA 87 topoisomerase thereby killing rapidly proliferating tumor cells (4) (5) . further metabolism in both liver and intestine by UDT-glucuronosyltransferase (UGT) 89 which conjugates it with glucuronic acid to form the inactive . This non-90 toxic form of the drug is then eliminated into gastrointestinal (GI) tract (8). In intestines, 91 bacterial β-glucuronidase (GUS) enzymes in the microbiota, such as Escherichia coli (E. 
Materials and Methods
126
Computational details
127
Molecular Docking Protocol
128
The complex structure of bacterial GUS with Inhibitor 2 was taken from the in the crystal structure were kept in the receptor. Then, the structure model was 135 subjected to "Protein Preparation Wizard" workflow in Maestro (version 9.2) to assign 136 hydrogens. The docking grid was generated using "Receptor Grid Generation" with 137 center on the original ligand and internal size of 10 × 10 × 10 Å. The ligands were 138 prepared using Ligprep 2.5 with MMFF force field from Schrodinger suite (19) . Glide SP 139 parameter set was applied in the docking protocol. The top ranking models by glide 140 score were selected as the final binding mode.
Molecular Dynamics Simulation
142
The docking poses were used as the initial structure in MD simulation. The 143 ligands were optimized at the Hartree-Fock level with the 6-31G (d,p) basis set using
144
Gaussian 09 (20) and then restrained electrostatic potential (RESP) charges were 145 calculated using the B3LYP/cc-pVTZ quantum mechanical method. The Amber ff99SB 146 force field (21) and general Amber force field (GAFF) (22) were applied to proteins and 147 ligands, respectively. All MD simulations were carried out using AMBER11(23) on
148
BlueBiou of the IBM cluster at Rice University using 32 cores with the same protocol.
149
Each simulation system was put in a truncated octahedron periodic box of SPC water 150 molecules with a margin of 10.0 Å along each dimension, and sodium ions were added 151 to maintain charge neutrality. All covalent bonds to hydrogen atoms were constrained 152 using the SHAKE algorithm (24). Electrostatic interactions were calculated using the 153 particle-mesh Ewald (PME) algorithm. A cutoff of 10 Å was applied to Lennard-Jones 154 interactions (25). 500 steps steepest-descent minimization followed by 1500 steps 155 conjugated gradient minimization were applied to the system. Then it was heated up 156 from 0 to 300 K gradually over 20 ps using the NVT ensemble with the solutes 157 restrained by a weak harmonic potential. Afterward, 160 ps equilibrations were carried 158 out in the NPT ensemble via three steps: the solutes were restrained while the waters 159 and counter ions were equilibrated in the first 60 ps; then protein were relaxed in the 160 next 20 ps; and all of the restraints were removed in the last 80 ps. Finally, the 161 production MD simulations were conducted at 1 atm and 300 K under the NPT 162 ensemble for 4 ns. Temperature was controlled using Langevin dynamics (26). The last 163 2 ns trajectory from production simulation was used to obtain the snapshots for was dissolved in ddH20 to make a stock of 20 mg/mL and stored at room temperature 177 for a maximum of 2 hours prior to use. As vehicle control, all animals received an 178 equivalent volume (compared to experimental groups) of 1% DMSO (ddH20) solution.
179
Healthy 6-8 week old female Balb/cJ mice (000651) were obtained from Jackson
180
Laboratories, Bar Harbor, ME. Mice were housed in conventional metabolic cages 181 (N=1/cage). All studies were conducted in accordance with the guidelines of the Animal
182
Care and Use Committee of Houston Methodist Research Institute.
183
The well-described CT-26 cell line, derived from a murine Balb/c colon with amoxapine, and it is the closest analog to inhibitor 2 and has been tested in 199 animals (13) (Supp. Fig. S1 ). Total injected volume for drugs or vehicles was identical Windows, version 11.0). To determine the differences across multiple groups, one-way
219
ANOVA was carried out. Independent two-sample t-test was conducted to detect 220 difference in means between two groups. Data were summarized as means ± standard 221 deviation (SD). P<0.05 was considered statistically significant. (Fig. 2) observed in all the systems, but the RMSD for loxapine system is much larger than the 259 others, which indicates reorientation and relocation occurred during the simulation.
222
Results
223
Analysis of Binding Modes obtained from docking
260
AMOX and 7/8 hydroxy metabolites conducted almost the same binding poses before 261 and after the simulation, while loxapine moved a lot during the process (Supp. Fig. S2 ).
262
The energetically unfavorable conformations usually result in a reorientation of the respectively, in the GUS enzyme assay (Fig. 3A) . The cell-based assay involves the 288 measurement of GUS enzymatic activity in live, intact E. coli bacteria. AMOX, 7-
289
OHAMOX and 8-OHAMOX generated IC50 values and SDs of 58 ± 5 nM, 41 ± 6 nM 290 and 100 ± 1 nM, respectively (Fig. 3B) . A bacterial cytotoxicity assay using these same 291 compounds indicated no toxicity to the bacterial cells at 2 and 20 µM (Fig. 3C) . Thus, staining around the anus. Diarrhea was first observed on day 7 of daily CPT-11 316 treatment with 50% of the mice from the CPT-11 group exhibiting diarrhea, while 10% of 317 the Amox-1mg group had diarrhea (Fig. 4A) . Peak efficacy was apparent on day 8 when 318 65% of the mice from the CPT-11 group exhibited diarrhea staining compared to only 10% 319 of the mice in the Amox-1mg group. By day 9, 90% of the CPT-11 mice had diarrhea 320 compared to 50% of Amox-1mg group. The Amox-5mg treatment totally prevented the 321 appearance of diarrhea on day 7, and on days 8 and 9, only 20% and 30% of the mice, 322 respectively, in the Amox-5mg group showed diarrhea. 30% of the mice in both the 323 amoxapine groups never showed diarrhea during the course of the entire study, and the 324 body weight of the survived mice showed rapid recovery (about 50% of the lost weight) 4 days after the cessation of CPT-11. The previously published GUSi Inhibitor 1 (13) 326 was also included in this study as a positive control. Overall, amoxapine (1 or 5 mg/kg) 327 had similar efficacy as Inhibitor 1 in suppressing diarrhea (Fig. 4A ). In addition, diarrhea 328 staining in the CPT-11 group was much more severe than diarrhea staining in the Amox 329 groups. Staining in mice from the CPT-11 group was darker (bloodier) and more liquid,
330
and consequently, all mice in the CPT-11 group had to be euthanized before or on day 331 12. Mice in the Amox-5mg group had a significant delay on the euthanization survival 332 plot (p=0.004, log-rank test) (Fig. 4B) , even more of a delay than the Inhibitor 1 control.
333
Thus, in addition to the frequency of diarrhea being reduced, the euthanization data 334 indicated that the severity of diarrhea was also attenuated by amoxapine. observed in jejunum and ilenum in damaged intestines (Fig. 5A ). In comparison with the 341 damage in the small intestine, the morphology of colon tissues in CPT-11-treated mice 342 showed similar changes (Fig. 5A) . In contrast, oral administration of amoxapine 343 protected the glandular structure of the intestinal and colon tissues (Fig. 5A) Table S2 ). The protective effect of amoxapine was further studied by immufluorescence 345 staining using the proliferative marker Ki67 and cell membrane marker β-catenin 346 ( Fig.5B-C) . Severe proliferative cell loss was observed in CPT-11-treated mice, implying 347 a difficult recovery from the damage, in accordance with the loss of cell membrane (Fig. 4C) . Throughout the experiment, the average tumor size of 355 mice in the Amox-1mg group was as low as, if not lower than, the average tumor size of 356 CPT-11 group mice. This data suggested that the 1mg/kg dose of amoxapine, which 357 possessed anti-diarrhea efficacy, had absolutely no effect on diminishing the tumor- 
397
Amoxapine is identified as a potent and selective GUSi that may satisfy the 398 aforementioned criteria. In addition, amoxapine has further advantages to strengthen 399 the case for repositioning it for this new indication. Co-treatment of 5 mg/kg amoxapine 400 with CPT-11 yielded enhanced effect in reducing tumor growth in mice, which was not 401 found in mice treated with Inhibitor 1 (Fig. 4C) . We speculate that the observed DOI: 10.1158 /1078 be determined in future work. Nevertheless, as an old drug, amoxapine has been 418 carefully evaluated for side effects and toxicity in human body and its PK/PD properties 419 have been comprehensively studied. It has the advantage to be translated to patients in 420 a relatively short period compared to the de novo discovered compounds (e.g. Inhibitor 421 1 or 2).
422
Amoxapine is an FDA approved drug and has been used in treatment of major 
432
The in silico and in vitro results showed that both 7-OHAMOX and 8-OHAMOX are 433 potent GUS inhibitors, which likely contributed to the efficacy of AMOX against diarrhea 434 in vivo. In both groups of AMOX, 1 mg/kg/day and 5 mg/kg/day orally in combination 435 with CPT-11(IP), significant suppression of severe diarrhea was observed starting on 436 day 7 (Fig. 4C) . About 30% of the mice receiving amoxapine never showed diarrhea 437 during the course of the study.
438
Despite the observed efficacy, it is noted that the diarrhea could not be fully Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 day 7-9, but at day 12, 70% of the mice still progressed to severe diarrhea. Interestingly, 441 this phenomenon was the same for the mice receiving Inhibitor 1 treatment (13). It 442 should be noted that GUS is not the only factor leading to the diarrhea. The intestine in 443 both humans and rodents is also rich in carboxylesterase (CES) and UGT enzymes. 
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The compounds were tested in triplicate at these concentrations and activity was 624 normalized to control wells (± bacteria). The antibiotic kanamycin (Kan) was included as Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 Amoxapine was gavaged at 1mg/kg/day or 5mg/kg/day for 12 days with daily i.p. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 
